CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Krilogy Financial LLC

Krilogy Financial LLC lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 92.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 20,872 shares of the company’s stock after buying an additional 10,050 shares during the quarter. Krilogy Financial LLC’s holdings in CRISPR Therapeutics were worth $1,127,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Global Trust Asset Management LLC raised its holdings in shares of CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after buying an additional 300 shares during the period. GPS Wealth Strategies Group LLC lifted its stake in CRISPR Therapeutics by 99.7% in the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares during the last quarter. Riggs Asset Managment Co. Inc. grew its holdings in CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares in the last quarter. Principal Securities Inc. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at approximately $41,000. Finally, NBC Securities Inc. raised its holdings in shares of CRISPR Therapeutics by 257.6% in the 1st quarter. NBC Securities Inc. now owns 608 shares of the company’s stock valued at $41,000 after purchasing an additional 438 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Robert W. Baird increased their target price on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Barclays cut their target price on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. Oppenheimer lowered their price target on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective for the company. Finally, Citigroup cut their price target on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, May 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $75.63.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock traded up $0.92 during mid-day trading on Wednesday, reaching $49.99. 1,108,313 shares of the company were exchanged, compared to its average volume of 1,573,917. The firm’s 50-day simple moving average is $55.02 and its two-hundred day simple moving average is $61.96. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10. The firm has a market cap of $4.25 billion, a PE ratio of -18.17 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.98) earnings per share. As a group, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.52 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.